Journal for ImmunoTherapy of Cancer

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
Sen Yan, Han Zeng, Kaifeng Jin, Fei Shao, Zhaopei Liu, Yuan Chang, Yiwei Wang, Yu Zhu, Zewei Wang, Le Xu, Jiejie Xu

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004569; DOI: 10.1136/jitc-2022-004569
Genomic profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: a secondary analysis of the CLAP trial
Xin Huang, Minjun He, Hongyu Peng, Chongjie Tong, Zhimin Liu, Xiaolong Zhang, Yang Shao, Dongqin Zhu, Junli Zhang, Jiani C Yin, Fan Yang, Chunyan Lan

Journal for ImmunoTherapy of Cancer May 2021, 9 (5) e002223; DOI: 10.1136/jitc-2020-002223
Checkpoint blockade accelerates a novel switch from an NKT-driven TNFα response toward a T cell driven IFN-γ response within the tumor microenvironment
Shota Aoyama, Ryosuke Nakagawa, Satoshi Nemoto, Patricio Perez-Villarroel, James J Mulé, Adam William Mailloux

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002269; DOI: 10.1136/jitc-2020-002269
Immune checkpoint inhibitor treatment and atherosclerotic cardiovascular disease: an emerging clinical problem
Kikkie Poels, Suzanne I.M. Neppelenbroek, Marie José Kersten, M. Louisa Antoni, Esther Lutgens, Tom T.P. Seijkens

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002916; DOI: 10.1136/jitc-2021-002916
Attenuating CD3 affinity in a PSMAxCD3 bispecific antibody enables killing of prostate tumor cells with reduced cytokine release
Kevin Dang, Giulia Castello, Starlynn C Clarke, Yuping Li, Aarti Balasubramani, Andrew Boudreau, Laura Davison, Katherine E Harris, Duy Pham, Preethi Sankaran, Harshad S Ugamraj, Rong Deng, Serena Kwek, Alec Starzinski, Suhasini Iyer, Wim van Schooten, Ute Schellenberger, Wenchao Sun, Nathan D Trinklein, Roland Buelow, Ben Buelow, Lawrence Fong, Pranjali Dalvi

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002488; DOI: 10.1136/jitc-2021-002488
Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma
Yousef Zakharia, Robert R McWilliams, Olivier Rixe, Joseph Drabick, Montaser F Shaheen, Kenneth F Grossmann, Ravindra Kolhe, Rafal Pacholczyk, Ramses Sadek, Lucinda L Tennant, Christopher M Smith, Eugene P Kennedy, Charles J Link Jr, Nicholas N Vahanian, Jiayi Yu, Steven S Shen, Erik L Brincks, Gabriela R Rossi, David Munn, Mohammed Milhem

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002057; DOI: 10.1136/jitc-2020-002057
Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
Libin Zhang, Yanhui Chen, Han Wang, Zheyuan Xu, Yang Wang, Sixing Li, Jun Liu, Yun Chen, Hongli Luo, Lijia Wu, Ying Yang, Henghui Zhang, Hao Peng

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002356; DOI: 10.1136/jitc-2021-002356
Intracerebral administration of CTLA-4 and PD-1 immune checkpoint blocking monoclonal antibodies in patients with recurrent glioblastoma: a phase I clinical trial
Johnny Duerinck, Julia Katharina Schwarze, Gil Awada, Jens Tijtgat, Freya Vaeyens, Cleo Bertels, Wietse Geens, Samuel Klein, Laura Seynaeve, Louise Cras, Nicky D’Haene, Alex Michotte, Ben Caljon, Isabelle Salmon, Michaël Bruneau, Mark Kockx, Sonia Van Dooren, Anne-Marie Vanbinst, Hendrik Everaert, Ramses Forsyth, Bart Neyns

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002296; DOI: 10.1136/jitc-2020-002296
Prospective real-world study on the pharmacokinetics of pembrolizumab in patients with solid tumors
Daan P. Hurkmans, Sebastiaan D.T. Sassen, Karlijn de Joode, Lisanne Putter, Edwin A. Basak, Annemarie J.M. Wijkhuijs, Markus Joerger, Reno Debets, Birgit C.P. Koch, Cor H. Van der Leest, Marco W.J. Schreurs, Astrid A.M. van der Veldt, Joachim G.J.V. Aerts, Ron H.J. Mathijssen, Stijn L.W. Koolen

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002344; DOI: 10.1136/jitc-2021-002344
Mesoporous silica nanoparticles inflame tumors to overcome anti-PD-1 resistance through TLR4-NFκB axis
Mayu Sun, Pengfei Gu, Yang Yang, Luodan Yu, Zheshun Jiang, Jingquan Li, Yingying Le, Yu Chen, Qian Ba, Hui Wang

Journal for ImmunoTherapy of Cancer Jun 2021, 9 (6) e002508; DOI: 10.1136/jitc-2021-002508

Main menu

Journal for ImmunoTherapy of Cancer

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Journal for ImmunoTherapy of Cancer

Pages